Valuation: NuCana plc

Market Cap 4.02M 3.54M 3.29M 3.02M 5.68M 386M 5.75M 39.14M 15.29M 191M 15.11M 14.78M 659M P/E 2024
-0.15x
P/E 2025 -0.2x
Enterprise Value -19.55M -17.19M -16M -14.69M -27.59M -1.87B -27.95M -190M -74.27M -926M -73.39M -71.81M -3.2B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day+1.94%
1 week+0.38%
Current month-13.49%
1 month-16.77%
3 months-40.50%
6 months-55.42%
Current year-63.47%
1 week 1.28
Extreme 1.28
1.41
1 month 1.21
Extreme 1.21
1.68
Current year 1.21
Extreme 1.21
3.81
1 year 1.21
Extreme 1.21
12.36
3 years 1.21
Extreme 1.21
4,105
5 years 1.21
Extreme 1.21
16,598.5
10 years 1.21
Extreme 1.21
160,000
Manager TitleAgeSince
Chief Executive Officer 58 2008-03-19
Director of Finance/CFO - 2018-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 58 2008-03-19
Director/Board Member 68 2009-12-13
Director/Board Member 72 2018-04-30
Date Insider Type Main position Quantity % Market Cap.
6/19/26 Issuer sale

Director

-23,811,896 74.8539%
6/19/26 Issuer sale

Chief Technology Officer

-36,539,720 114.8645%
4/15/26 Free

Chief Operating Officer

132,600,130 416.8354%
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%+0.38%-88.05%-99.97% 5.37M
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-1.10%-1.35%+3.75%+417.50% 23.18B
+2.96%-0.39%-18.61%-12.57% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.21%+0.87%+26.19%+185.79% 13.92B
Average +0.87%+1.26%+29.17%+150.00% 24.01B
Weighted average by Cap. +0.09%+1.93%+39.92%+138.65%

Financials

2024 2025
Net sales - -
Net income -19M -16.7M -15.55M -14.28M -26.81M -1.82B -27.16M -185M -72.17M -900M -71.31M -69.78M -3.11B -29.35M -25.8M -24.02M -22.06M -41.42M -2.81B -41.97M -286M -112M -1.39B -110M -108M -4.8B
Net Debt -6.56M -5.77M -5.37M -4.93M -9.26M -629M -9.38M -63.8M -24.92M -311M -24.62M -24.09M -1.07B -23.58M -20.72M -19.29M -17.72M -33.27M -2.26B -33.71M -229M -89.56M -1.12B -88.5M -86.59M -3.86B
Logo NuCana plc
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Employees
11
Date Price Change Volume
26-07-27 US$1.315 +1.94% 24,823
26-07-24 US$1.290 -3.01% 4,501
26-07-23 US$1.330 -2.21% 20,306
26-07-22 US$1.360 +5.43% 49,013
26-07-21 US$1.290 -1.53% 15,410

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NCNA Stock